GlassScriptPhysician profile
Andrew L Morrison
NPI 1750382628
$5,369.43
in general payments reported to CMS, 2019-2025
27 companies · $735 in 2025
The $735 reported for 2025 was more than what 80% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,353 · 2020: $651 · 2022: $17.41 · 2023: $125 · 2024: $487 · 2025: $735.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,348.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,347.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,320.14 | 2019-2025 | Airsupra, Fasenra, Farxiga |
| Glaxosmithkline, LLC. | $811.40 | 2019-2025 | Arexvy |
| Lilly USA, LLC | $486.86 | 2019-2025 | Mounjaro |
| Novo Nordisk INC | $468.23 | 2019-2025 | Ozempic |
| Pfizer INC. | $406.19 | 2019-2020 | |
| Amgen INC. | $384.40 | 2019-2020 | |
| Abbvie INC. | $285.87 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $186.84 | 2019 | |
| Merck Sharp & Dohme LLC | $184.79 | 2019-2020 | |
| Kowa Pharmaceuticals America, INC. | $153.03 | 2019-2025 | Zoryve |
| Mayne Pharma Commercial LLC | $125.00 | 2025 | |
| Astellas Pharma US INC | $105.47 | 2019 | |
| Kaleo, INC. | $60.98 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $56.84 | 2019 | |
| Amarin Pharma, INC. | $45.73 | 2019 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch Health US, LLC | $45.11 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $38.64 | 2020 | |
| Sanofi Pasteur INC. | $37.34 | 2019 | |
| Shire North American Group INC | $22.24 | 2019 | |
| Irhythm Technologies, INC. | $21.64 | 2019 | |
| Therapeuticsmd, INC. | $21.14 | 2019 | |
| Avanir Pharmaceuticals, INC. | $20.60 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $19.88 | 2019 | |
| Spinal Simplicity, LLC | $17.41 | 2022 | |
| Amag Pharmaceuticals, INC. | $16.68 | 2019 | |
| Nalpropion Pharmaceuticals LLC | $16.16 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $10.82 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Morrison listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.